Imbruvica godkänt vid WM

Janssen’s IMBRUVICA (ibrutinib) har fått godkänt av Europeiska Kommissionen för behandling av Waldenström’s Macroglobulinemi.

Ibrutinib now the first EC-approved treatment option available for this rare B-cell lymphoma

Beerse/Belgium, July 10, 2015 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA®▼ (ibrutinib) capsules as a treatment option for adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. This approval represents a significant step forward for patients suffering from WM. There were previously no treatment options approved across Europe for this rare and slow-growing type of blood cancer.

Läs den engelska pressreleasen HÄR